Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

IAMA Therapeutics

Request full access

Makes a difference in the lives of individuals suffering from neurodevelopmental, cognitive disorders

Genoa, ItalyFounded 2021Biotech & Life Sciences

About IAMA Therapeutics

IAMA Therapeutics is a clinical-stage pharmaceutical company, established in 2021 and headquartered in Genoa, Italy. The company emerged from a decade of research conducted at the Italian Institute of Technology (IIT) by the 'Brain Development and Disease' and 'Molecular Modeling and Drug Discovery' research groups, led by founders Laura Cancedda and Marco De Vivo. This foundational research, supported by Fondazione Telethon, focused on neurodevelopmental disorders and led to the discovery of a new class of drug candidates.

The company's core business revolves around discovering and developing small-molecule drugs that target cation-chloride cotransporters to address central nervous system (CNS) disorders. Its business model is centered on advancing these proprietary drug candidates through clinical trials to eventually commercialize them, providing new treatments for patients with neurological conditions. The company has successfully raised a total of $25.9M in capital over two funding rounds. A Series A round in April 2022 brought in €8 million from Claris Ventures and CDP Venture Capital. This was followed by a €15 million Series B round in April 2025, led by Indaco Venture Partners, to accelerate clinical development.

IAMA's lead product candidate is IAMA-6, an orally administered, selective inhibitor of the NKCC1 cotransporter. The NKCC1 protein is involved in transporting chloride ions into neurons; in many brain disorders, its dysregulated activity leads to an ion imbalance and neuronal hyperexcitability. By selectively inhibiting NKCC1, IAMA-6 aims to restore the natural chloride balance and reduce the pathological neuronal activity seen in conditions like epilepsy and autism. This mechanism has shown the potential to alleviate cognitive and behavioral symptoms in preclinical models. IAMA-6 entered a first-in-human Phase 1 clinical trial in January 2024 to evaluate its safety, tolerability, and pharmacokinetics. The company is targeting a range of orphan brain disorders, including drug-resistant epilepsy, Dravet syndrome, and autism spectrum disorders.

Source: Dealroom company data

At a glance

Status
Operational
Employees
10
Open positions
None listed
Dealroom signal
48.4/100
Industry
Health
Sub-industry
Pharmaceutical, Health Platform
Sector
Veterinary, Biotechnology, Neurology, Spinout, Pets, Hard Tech, DT and LS, science-based
Business model
SaaS
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VC✓Equity / VC Apr 2025 $5.5M $44M Indaco Venture Partners · CDP Venture Capital · Claris Ventures · Fondazione ENEA Tech ↗
EARLY VC✓Equity / VC Mar 2022 $8.8M $35M CDP Venture Capital · Claris Ventures ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

IAMA Therapeutics website traffic

Latest recorded traffic for IAMA Therapeutics is 790 monthly website visits, up 79.5% over the last three months. IAMA Therapeutics's team grew 11.1% over the past year.

Latest monthly visits790 3-month web change+79.5% 1-year team growth+11.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

IAMA Therapeutics in the Genoa ecosystem

Live from Dealroom

The IAMA Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • CDP Venture Capital
  • Claris Ventures
  • Fondazione ENEA Tech
  • Indaco Venture Partners

Other known investors1 additional known investor

  • Italian Institute of Technology
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
5 countries with
team presence
🇮🇹 Italy64.3%
🇺🇸 United States14.3%
🇩🇪 Germany7.1%
🇨🇭 Switzerland7.1%
🇩🇰 Denmark7.1%
5 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about IAMA Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See IAMA Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.